YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.
The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...